Tirofiban Combination Therapy for Acute Ischemic Stroke: A Systematic Review and Meta‐Analysis [PDF]
Introduction Acute ischemic stroke (AIS) is a leading cause of morbidity and mortality globally. Standard antiplatelet therapies, while partially effective, do not fully inhibit all pathways of platelet aggregation, leaving patients at risk of recurrent ...
Abdullah Bin Kamran+9 more
doaj +3 more sources
Local tirofiban infusion for remnant stenosis in large vessel occlusion: tirofiban ASSIST study [PDF]
Background Compared with embolic occlusions, intracranial atherosclerotic stenosis (ICAS)-related large vessel occlusions (LVOs) often require rescue treatment following mechanical thrombectomy (MT).
Yong-Won Kim+11 more
doaj +4 more sources
Effects of tirofiban on haemostatic activation in vitro [PDF]
Thrombin plays a critical role in normal haemostasis and pathological thrombosis. Heparin has long been a mainstay choice of antithrombotic regimen in cardiac patients, but persistent thrombin generation seems to occur during heparin therapy. Because platelets are integral to primary haemostasis and clot formation, we evaluated the use of tirofiban ...
Kenichi A. Tanaka+5 more
openalex +4 more sources
Tirofiban-induced acute profound thrombocytopenia in endovascular therapy for acute ischemic stroke: a rare case report [PDF]
Background Studies have shown that tirofiban (a glycoprotein IIb/IIIa receptor antagonist) is effective in the endovascular treatment of cerebrovascular diseases. However, it has also been reported that tirofiban can cause thrombocytopenia.
Jiuling Liu+4 more
doaj +2 more sources
Tirofiban-Induced Profound Thrombocytopenia: A Case Report. [PDF]
Platelet glycoprotein IIB/IIIA antagonists are potent inhibitors of platelet aggregation. Although the incidence of thrombocytopenia following their administration is relatively low, it can sometimes lead to fatal consequences. We report a case of a 57-year-old gentleman presenting with non-ST elevation myocardial infarction complicated with tirofiban ...
Al Achkar Z+3 more
europepmc +3 more sources
Platelet integrin αIIbβ3 plays a key role in a venous thrombogenesis mouse model [PDF]
Venous thrombosis (VT) is a common vascular disease associated with reduced survival and a high recurrence rate. VT is initiated by the accumulation of platelets and neutrophils at sites of endothelial cell activation. A role for platelet αIIbβ3 in VT is
Brian D. Adair+14 more
doaj +2 more sources
Safety of Tirofiban in Acute Ischemic Stroke [PDF]
Background and Purpose— Tirofiban is a highly selective, fast-acting nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist with a short half-life time. Glycoprotein IIb/IIIa antagonists are effective for the treatment of acute coronary syndromes proven in large clinical trials.
Otto W Witte, Arno Villringer
exaly +5 more sources
Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban [PDF]
Christopher P Cannon+2 more
exaly +2 more sources
Safety of tirofiban and dual antiplatelet therapy in treating intracranial aneurysms
Background Endovascular treatment of intracranial aneurysms usually involves stent-assisted coiling (SAC) and flow diverters. Glycoprotein IIb/IIIa inhibitors such as tirofiban and dual antiplatelet therapy (DAPT) are required to prevent thromboembolic ...
Edgar A Samaniego+2 more
exaly +3 more sources
A fatal complication of tirofiban in an octogenarian: Diffuse alveolar hemorrhage [PDF]
An 84-year-old female patient with a past medical history significant for hypertension and diabetes mellitus, was admitted to the Emergency Department with acute coronary syndrome and complete atrioventricular block. She underwent a successful primary percutaneous coronary intervention.
Erkan İlhan+7 more
openalex +4 more sources